Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers

详细信息    查看全文

• 作者：Paul A. Goepfert ; Georgia D. Tomaras ; Helen Horton ; David Montefiori ; Guido Ferrari ; Mark Deers ; Gerald Voss ; Marguerite Koutsoukos ; Louise Pedneault ; Pierre V ; epapeliere ; et al.
• 关键词：HIV vaccine ; Clinical trial ; Nef ; Tat ; gp120 ; AS02A adjuvant
• 刊名：Vaccine
• 出版年：2007
• 出版时间：5 January 2007
• 年：2007
• 卷：25
• 期：3
• 页码：510-518
• 全文大小：481 K

文摘

>Background

Use of the recombinant proteins NefTat and gp120_W61D formulated with the AS02A adjuvant system was previously shown to protect against AIDS in a rhesus macaque SHIV animal model system.

Methods

Eighty-four HIV uninfected human participants were vaccinated intramuscularly at 0, 1, and 3 months and evaluated for safety. Immune responses were analyzed for the presence of vaccine-induced antibody and T lymphocyte responses.

Results

The vaccines were safe and well tolerated at all doses. Nef-, Tat-, and gp120-specific binding antibodies were induced in all individuals that received the respective antigen, lasting up to 9 months after the final immunization. Antibodies able to neutralize the T-cell laboratory-adapted strain of HIV-1_W61D were detected in the majority of vacinees, but did not neutralize primary isolates. Envelope-specific antibody-dependent cell cytoxicity was detected in most of the individuals receiving gp120. Robust and persistent HIV-specific lymphoproliferative responses were detected against all subunit proteins in the majority of immunized participants. As expected, HIV-specific CD8 T-cell responses were not detected.

Conclusions

Despite the lack of primary isolate neutralizing antibody induction, the observed high frequency and magnitude of other immune responses warrant further work with this vaccine or vaccine components.